Close Menu

NEW YORK – Guardant Health said today that it has priced an underwritten public offering of 11.5 million shares of its common stock at a $84 per share.

The offering is expected to close on June 4.

Guardant is selling 3,750,000 of the shares and SoftBank Investment Advisers is selling the other 7,750,000 shares. The total, for which JP Morgan Securities is acting as sole book-running manager, was increased from a previously announced 10 million shares of common stock.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Nature News reports on how meeting cancellations and related costs are affecting scientific societies.

In a new ruling, Canada's Supreme Court upheld the country's genetic non-discrimination law, the Canadian Press reports.

COVID-19 vaccine developers aim to avoid a complication that has affected efforts to develop vaccines for other diseases, the Wall Street Journal reports.

In PLOS this week: analysis of insertions throughout Shigella genomes, antigen production in malaria parasites, and more.